O	0	7	Imaging
O	8	17	Protocols
O	18	20	in
O	21	29	Clinical
O	30	37	Studies
O	38	40	in
B-Disease	41	49	Advanced
I-Disease	50	53	Age
I-Disease	53	54	-
I-Disease	54	61	Related
I-Disease	62	69	Macular
I-Disease	70	82	Degeneration
O	82	83	:
O	84	99	Recommendations
O	100	104	from
O	105	119	Classification
O	120	122	of
B-Symptom	123	130	Atrophy
O	131	140	Consensus
O	141	149	Meetings
O	149	150	.

O	152	154	To
O	155	164	summarize
O	165	168	the
O	169	176	results
O	177	179	of
O	180	181	2
O	182	191	consensus
O	192	200	meetings
O	201	202	(
O	202	216	Classification
O	217	219	of
B-Symptom	220	227	Atrophy
O	228	235	Meeting
O	236	237	[
O	237	240	CAM
O	240	241	]
O	241	242	)
O	243	245	on
O	246	258	conventional
O	259	262	and
O	263	271	advanced
O	272	279	imaging
O	280	290	modalities
O	291	295	used
O	296	298	to
O	299	305	detect
O	306	309	and
O	310	318	quantify
B-Symptom	319	326	atrophy
O	327	330	due
O	331	333	to
B-Disease	334	338	late
I-Disease	338	339	-
I-Disease	339	344	stage
I-Disease	345	348	non
I-Disease	348	349	-
I-Disease	349	360	neovascular
I-Disease	361	364	and
I-Disease	365	376	neovascular
I-Disease	377	380	age
I-Disease	380	381	-
I-Disease	381	388	related
I-Disease	389	396	macular
I-Disease	397	409	degeneration
O	410	411	(
B-Disease	411	414	AMD
O	414	415	)
O	416	419	and
O	420	422	to
O	423	430	provide
O	431	446	recommendations
O	447	449	on
O	450	453	the
O	454	457	use
O	458	460	of
O	461	466	these
O	467	477	modalities
O	478	480	in
O	481	488	natural
O	489	496	history
O	497	504	studies
O	505	508	and
O	509	523	interventional
O	524	532	clinical
O	533	539	trials
O	539	540	.

O	541	551	Systematic
O	552	558	debate
O	559	561	on
O	562	565	the
O	566	575	relevance
O	576	578	of
O	579	587	distinct
O	588	595	imaging
O	596	606	modalities
O	607	611	held
O	612	614	in
O	615	616	2
O	617	626	consensus
O	627	635	meetings
O	635	636	.

O	637	638	A
O	639	644	panel
O	645	647	of
B-Anatomy	648	654	retina
O	655	666	specialists
O	666	667	.

O	668	674	During
O	675	678	the
O	679	682	CAM
O	682	683	,
O	684	685	a
O	686	696	consortium
O	697	699	of
O	700	713	international
O	714	721	experts
O	722	731	evaluated
O	732	735	the
O	736	746	advantages
O	747	750	and
O	751	764	disadvantages
O	765	767	of
O	768	775	various
O	776	783	imaging
O	784	794	modalities
O	795	797	on
O	798	801	the
O	802	807	basis
O	808	810	of
O	811	814	the
O	815	825	collective
O	826	834	analysis
O	835	837	of
O	838	839	a
O	840	845	large
O	846	852	series
O	853	855	of
O	856	864	clinical
O	865	870	cases
O	870	871	.

O	872	873	A
O	874	884	systematic
O	885	895	discussion
O	896	898	on
O	899	902	the
O	903	907	role
O	908	910	of
O	911	915	each
O	916	924	modality
O	925	927	in
O	928	934	future
O	935	942	studies
O	943	945	in
B-Disease	946	949	non
I-Disease	949	950	-
I-Disease	950	961	neovascular
I-Disease	962	965	and
I-Disease	966	977	neovascular
I-Disease	978	981	AMD
O	982	985	was
O	986	990	held
O	990	991	.

O	992	1002	Advantages
O	1003	1006	and
O	1007	1020	disadvantages
O	1021	1023	of
O	1024	1031	current
B-Diagnostic_tool	1032	1039	retinal
I-Diagnostic_tool	1040	1047	imaging
I-Diagnostic_tool	1048	1060	technologies
O	1061	1064	and
O	1065	1080	recommendations
O	1081	1084	for
O	1085	1090	their
O	1091	1094	use
O	1095	1097	in
B-Disease	1098	1106	advanced
I-Disease	1107	1110	AMD
O	1111	1117	trials
O	1117	1118	.

O	1119	1126	Imaging
O	1127	1136	protocols
O	1137	1139	to
O	1140	1146	detect
O	1146	1147	,
O	1148	1156	quantify
O	1156	1157	,
O	1158	1161	and
O	1162	1169	monitor
O	1170	1181	progression
O	1182	1184	of
B-Symptom	1185	1192	atrophy
O	1193	1199	should
O	1200	1207	include
B-Diagnostic_tool	1208	1213	color
I-Diagnostic_tool	1214	1220	fundus
I-Diagnostic_tool	1221	1232	photography
O	1233	1234	(
B-Diagnostic_tool	1234	1237	CFP
O	1237	1238	)
O	1238	1239	,
B-Diagnostic_tool	1240	1248	confocal
I-Diagnostic_tool	1249	1255	fundus
I-Diagnostic_tool	1256	1272	autofluorescence
O	1273	1274	(
B-Diagnostic_tool	1274	1277	FAF
O	1277	1278	)
O	1278	1279	,
B-Diagnostic_tool	1280	1288	confocal
I-Diagnostic_tool	1289	1293	near
I-Diagnostic_tool	1293	1294	-
I-Diagnostic_tool	1294	1302	infrared
I-Diagnostic_tool	1303	1314	reflectance
O	1315	1316	(
B-Diagnostic_tool	1316	1319	NIR
O	1319	1320	)
O	1320	1321	,
O	1322	1325	and
B-Diagnostic_tool	1326	1330	high
I-Diagnostic_tool	1330	1331	-
I-Diagnostic_tool	1331	1341	resolution
I-Diagnostic_tool	1342	1349	optical
I-Diagnostic_tool	1350	1359	coherence
I-Diagnostic_tool	1360	1370	tomography
I-Diagnostic_tool	1371	1377	volume
I-Diagnostic_tool	1378	1383	scans
O	1383	1384	.

O	1385	1390	These
O	1391	1397	images
O	1398	1404	should
O	1405	1407	be
O	1408	1416	acquired
O	1417	1419	at
O	1420	1427	regular
O	1428	1437	intervals
O	1438	1448	throughout
O	1449	1452	the
O	1453	1458	study
O	1458	1459	.

O	1460	1462	In
O	1463	1470	studies
O	1471	1473	of
B-Disease	1474	1477	non
I-Disease	1477	1478	-
I-Disease	1478	1489	neovascular
I-Disease	1490	1493	AMD
O	1494	1495	(
O	1495	1502	without
O	1503	1510	evident
O	1511	1516	signs
O	1517	1519	of
B-Symptom	1520	1526	active
I-Symptom	1527	1529	or
I-Symptom	1530	1539	regressed
I-Symptom	1540	1558	neovascularization
O	1559	1560	[
B-Symptom	1560	1562	NV
O	1562	1563	]
O	1564	1566	at
O	1567	1575	baseline
O	1575	1576	)
O	1576	1577	,
B-Diagnostic_tool	1578	1581	CFP
O	1582	1585	may
O	1586	1588	be
O	1589	1599	sufficient
O	1600	1602	at
O	1603	1611	baseline
O	1612	1615	and
O	1616	1619	end
O	1619	1620	-
O	1620	1622	of
O	1622	1623	-
O	1623	1628	study
O	1629	1634	visit
O	1634	1635	.

B-Diagnostic_tool	1636	1647	Fluorescein
I-Diagnostic_tool	1648	1659	angiography
O	1660	1661	(
B-Diagnostic_tool	1661	1663	FA
O	1663	1664	)
O	1665	1668	may
O	1669	1675	become
O	1676	1685	necessary
O	1686	1688	to
O	1689	1697	evaluate
O	1698	1701	for
B-Symptom	1702	1704	NV
O	1705	1707	at
O	1708	1711	any
O	1712	1717	visit
O	1718	1724	during
O	1725	1728	the
O	1729	1734	study
O	1734	1735	.

B-Diagnostic_tool	1736	1747	Indocyanine
I-Diagnostic_tool	1747	1748	-
I-Diagnostic_tool	1748	1753	green
I-Diagnostic_tool	1754	1765	angiography
O	1766	1767	(
B-Diagnostic_tool	1767	1770	ICG
I-Diagnostic_tool	1770	1771	-
I-Diagnostic_tool	1771	1772	A
O	1772	1773	)
O	1774	1777	may
O	1778	1780	be
O	1781	1791	considered
O	1792	1794	at
O	1795	1803	baseline
O	1804	1809	under
O	1810	1817	certain
O	1818	1828	conditions
O	1828	1829	.

O	1830	1833	For
O	1834	1841	studies
O	1842	1844	in
O	1845	1853	patients
O	1854	1858	with
B-Disease	1859	1870	neovascular
I-Disease	1871	1874	AMD
O	1874	1875	,
O	1876	1885	increased
O	1886	1890	need
O	1891	1894	for
O	1895	1908	visualization
O	1909	1911	of
O	1912	1915	the
B-Anatomy	1916	1927	vasculature
O	1928	1932	must
O	1933	1935	be
O	1936	1941	taken
O	1942	1946	into
O	1947	1954	account
O	1954	1955	.

O	1956	1967	Accordingly
O	1967	1968	,
O	1969	1974	these
O	1975	1982	studies
O	1983	1989	should
O	1990	1997	include
B-Diagnostic_tool	1998	2000	FA
O	2001	2002	(
O	2002	2013	recommended
O	2014	2016	at
O	2017	2025	baseline
O	2026	2029	and
O	2030	2038	selected
O	2039	2045	follow
O	2045	2046	-
O	2046	2048	up
O	2049	2055	visits
O	2055	2056	)
O	2057	2060	and
B-Diagnostic_tool	2061	2064	ICG
I-Diagnostic_tool	2064	2065	-
I-Diagnostic_tool	2065	2066	A
O	2067	2072	under
O	2073	2080	certain
O	2081	2091	conditions
O	2091	2092	.

O	2093	2094	A
O	2095	2105	multimodal
O	2106	2113	imaging
O	2114	2122	approach
O	2123	2125	is
O	2126	2137	recommended
O	2138	2140	in
O	2141	2149	clinical
O	2150	2157	studies
O	2158	2161	for
O	2162	2165	the
O	2166	2173	optimal
O	2174	2183	detection
O	2184	2187	and
O	2188	2199	measurement
O	2200	2202	of
B-Symptom	2203	2210	atrophy
O	2211	2214	and
O	2215	2218	its
O	2219	2229	associated
O	2230	2238	features
O	2238	2239	.

O	2240	2248	Specific
O	2249	2259	validation
O	2260	2267	studies
O	2268	2272	will
O	2273	2275	be
O	2276	2285	necessary
O	2286	2288	to
O	2289	2298	determine
O	2299	2302	the
O	2303	2307	best
O	2308	2319	combination
O	2320	2322	of
O	2323	2330	imaging
O	2331	2341	modalities
O	2341	2342	,
O	2343	2346	and
O	2347	2352	these
O	2353	2368	recommendations
O	2369	2373	will
O	2374	2378	need
O	2379	2381	to
O	2382	2384	be
O	2385	2392	updated
O	2393	2395	as
O	2396	2399	new
O	2400	2407	imaging
O	2408	2420	technologies
O	2421	2427	become
O	2428	2437	available
O	2438	2440	in
O	2441	2444	the
O	2445	2451	future
O	2451	2452	.
